CYTO
|Altamira Therapeutics Ltd
NASDAQ
USD
|%
Current Price
Change
(%)
P/E Ratio
0.16
Dividend Yield
Market Cap
1.13M
Volume
Open
Previous Close
52-Week High
USD 1.59
52-Week Low
USD 0.10
About Altamira Therapeutics Ltd
Altamira Therapeutics Ltd. operates as a preclinical-stage biopharmaceutical company in Switzerland and Australia. The company develops and supplies OligoPhore/SemaPhore platforms, which are peptide-based nanoparticle technologies for ribonucleic acid delivery to extrahepatic tissues. Its commercial products include Bentrio, a drug-free nasal spray for personal protection against airborne viruses and allergens. The company is developing AM-401 for the treatment of KRAS driven cancer; AM-411 for ...
Sector:Healthcare
Industry:Biotechnology
CEO:Dr. Thomas Meyer Ph.D.
Employees:10
Headquarters:Hamilton, Bermuda
Website:altamiratherapeutics.com
Dividend History
Dividend Payments
| Declared Date | Record Date | Payment Date | Amount | Frequency |
|---|
Similar Companies
Explore Stocks by Sector
technology
finance
healthcare
Frequently Asked Questions